Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Entire COX-2 Class Is TARGET Of Critical Lancet Editorial

This article was originally published in The Pink Sheet Daily

Executive Summary

The TARGET study's mixed results on Novartis' Prexige prompted an editorial critique of the entire COX-2 inhibitor class of drugs.

You may also be interested in...



FDA To Hold COX-2 Advisory Committee In Early 2005, Woodcock Says

The agency will have to make a trade-off between getting products on the market and determining their cardiovascular safety profile. Merck believes placebo-controlled trials in osteoarthritis patients should not be longer than four months due to ethical concerns.

FDA To Hold COX-2 Advisory Committee In Early 2005, Woodcock Says

The agency will have to make a trade-off between getting products on the market and determining their cardiovascular safety profile. Merck believes placebo-controlled trials in osteoarthritis patients should not be longer than four months due to ethical concerns.

Prexige TARGET Study: Not Quite A Bull's-Eye For Novartis

The study found a lower risk of gastrointestinal side effects for Prexige compared to ibuprofen and naproxen, but the incidence of serious liver abnormalities was higher for the COX-2 than for the NSAIDs.

Related Content

Topics

UsernamePublicRestriction

Register

OM010563

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel